BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38040526)

  • 1. Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors.
    Wolf P; Maione L; Kamenický P; Chanson P
    Arch Med Res; 2023 Dec; 54(8):102921. PubMed ID: 38040526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone, acromegaly, and heart failure: an intricate triangulation.
    Saccà L; Napoli R; Cittadini A
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):660-71. PubMed ID: 14974906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acromegaly and it's cardiovascular implications].
    Cadena-Obando DA; Remba-Shapiro I; Abreu-Rosario CG; Mercado M
    Rev Med Inst Mex Seguro Soc; 2021 Feb; 59(1):73-80. PubMed ID: 33667046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acromegalic cardiomyopathy].
    Bencze A; Rácz K
    Orv Hetil; 2011 Nov; 152(47):1875-8. PubMed ID: 22042313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular consequences of early-onset growth hormone excess.
    Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
    Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
    Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of growth hormone in chronic heart failure: therapeutic implications.
    Volterrani M; Giustina A; Manelli F; Cicoira MA; Lorusso R; Giordano A
    Ital Heart J; 2000 Nov; 1(11):732-8. PubMed ID: 11110515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
    Lombardi G; Colao A; Marzullo P; Ferone D; Longobardi S; Esposito V; Merola B
    J Endocrinol; 1997 Oct; 155 Suppl 1():S33-7; discussion S39. PubMed ID: 9389993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-treatment heterogeneity of cardiometabolic risk in patients with acromegaly: The impact of GH and IGF-1.
    Heydari M; Hashemi-Madani N; Emami Z; Khajavi A; Ghorbani M; Malek M; Ataei Kachuee M; Khamseh ME
    Endocr Res; 2022 Feb; 47(1):1-7. PubMed ID: 34102938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of growth hormone in chronic heart failure. Therapeutic implications.
    Volterrani M; Manelli F; Cicoira M; Lorusso R; Giustina A
    Drugs; 2000 Oct; 60(4):711-9. PubMed ID: 11085197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular disturbances in acromegaly].
    Fedrizzi D; Czepielewski MA
    Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1416-29. PubMed ID: 19197449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular complications in acromegaly.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.